In an 83-year-old man with one month of proximal muscle weakness, elevated C-reactive protein and erythrocyte sedimentation rate, normal creatine kinase, and low-titer positive antinuclear antibody, what is the most likely diagnosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differential Diagnosis: Polymyalgia Rheumatica vs. Inflammatory Myositis

The most likely diagnosis is polymyalgia rheumatica (PMR), given the proximal muscle weakness (likely pain-limited rather than true weakness), markedly elevated inflammatory markers (CRP 73, ESR 74), normal CK, and age 83 years. 1, 2

Key Diagnostic Reasoning

Normal CK Rules Out True Myositis

  • Normal creatine kinase is the critical distinguishing feature that excludes inflammatory myositis and points toward PMR. 1, 3, 2
  • True myositis typically shows CK elevations with a median of approximately 2650 IU/L (range 335-20,270 IU/L), often >10 times the upper limit of normal in immune-mediated necrotizing myopathy. 4, 3
  • PMR characteristically presents with severe myalgia and functional limitation that mimics weakness, but CK levels remain within normal limits because there is no actual muscle damage. 1, 2

Clinical Pattern Fits PMR

  • The patient's age (83 years) falls within the typical PMR demographic, with average onset at 73 years. 5
  • Proximal muscle involvement affecting shoulders and hips is the hallmark of PMR, though what appears as "weakness" is actually pain-limited movement rather than true motor weakness. 2, 5, 6
  • Markedly elevated inflammatory markers (ESR 74, CRP 73) are present in over 90% of PMR cases and support the diagnosis. 5, 7

Low-Titer ANA (1:160) is Non-Specific

  • The ANA titer of 1:160 is low and non-specific in an elderly patient, and does not suggest a primary autoimmune connective tissue disease. 2
  • This level of ANA positivity can occur in normal elderly individuals and does not alter the PMR diagnosis. 2

Critical Next Steps

Confirm True Weakness vs. Pain-Limited Movement

  • Perform a careful physical examination to distinguish true motor weakness from pain-limited movement. 1, 2
  • In PMR, patients have full strength when pain is controlled, whereas true myositis shows objective motor weakness on manual muscle testing. 4, 1
  • Ask specifically about bilateral shoulder and hip girdle pain with severe morning stiffness (>45 minutes), which is pathognomonic for PMR. 2, 5, 6

Screen for Giant Cell Arteritis (GCA)

  • Immediately assess for GCA symptoms, as 20% of PMR patients have concurrent GCA, which requires higher-dose glucocorticoids to prevent blindness. 4, 2, 5
  • Ask about new headache, jaw claudication, visual changes (diplopia, amaurosis fugax), scalp tenderness, and temporal artery tenderness. 4, 6
  • If any GCA features are present, start prednisone 40-60 mg daily immediately and arrange urgent temporal artery ultrasound or biopsy. 4, 6

Exclude PMR Mimics

  • Complete the baseline laboratory workup to exclude conditions that mimic PMR: 2
    • Rheumatoid factor and anti-CCP antibodies to exclude elderly-onset rheumatoid arthritis (most common PMR mimic). 2, 8
    • Complete blood count to assess for anemia, thrombocytosis, or hematologic malignancy. 2, 8
    • Comprehensive metabolic panel (glucose, creatinine, liver enzymes) for baseline before glucocorticoid therapy. 2
    • Thyroid-stimulating hormone (TSH) to exclude thyroid disorders. 2
    • Protein electrophoresis to exclude paraproteinemia/multiple myeloma. 2, 8
    • Consider chest X-ray to exclude malignancy, as solid tumors can present with polymyalgia symptoms. 2, 8

Additional Muscle Enzyme Testing if Uncertainty Remains

  • If clinical suspicion for myositis persists despite normal CK, measure aldolase, AST, ALT, and LDH, as one may be elevated when CK is normal. 1, 3
  • Consider muscle MRI or biopsy only if additional muscle enzymes are elevated or true weakness is confirmed on examination. 1, 3

Therapeutic Trial as Diagnostic Confirmation

  • Initiate prednisone 15-20 mg daily (within the recommended 12.5-25 mg range for this elderly patient). 2
  • PMR responds dramatically within 48-72 hours, with near-complete resolution of symptoms within 1-2 weeks. 2, 5, 6
  • Lack of rapid, dramatic improvement should prompt immediate reassessment of the diagnosis and consideration of alternative conditions. 2, 8

Common Pitfalls to Avoid

  • Do not confuse pain-limited movement with true motor weakness—this is the most common diagnostic error leading to misdiagnosis of myositis. 1, 2
  • Do not miss concurrent GCA—always screen for cranial symptoms, as 20% of PMR patients have GCA requiring higher glucocorticoid doses. 4, 5, 6
  • Do not start prednisone <12.5 mg daily—subtherapeutic dosing leads to persistent symptoms and diagnostic uncertainty. 2
  • Do not overlook malignancy—solid tumors and hematologic malignancies can present with polymyalgia symptoms, especially if response to glucocorticoids is poor or atypical features are present. 2, 8
  • Do not forget osteoporosis prophylaxis—start calcium 1200-1500 mg and vitamin D 800-1000 IU daily immediately, with bisphosphonate therapy for this elderly patient. 2

Alternative Diagnoses to Consider if PMR is Excluded

  • Elderly-onset rheumatoid arthritis if RF/anti-CCP positive or peripheral joint synovitis develops. 2, 8
  • Seronegative symmetrical polyarthritis (SSP) if hand arthritis develops during follow-up (can occur in 5% of cases initially presenting as PMR). 8
  • Malignancy (solid tumor or hematologic) if poor response to appropriate-dose glucocorticoids or constitutional symptoms predominate. 2, 8
  • Hypothyroidism if TSH is elevated. 2
  • Statin-induced myopathy if patient is on statins, though CK would typically be elevated. 4

References

Guideline

Diagnosis and Evaluation of Myositis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Approach for Polymyalgia Rheumatica

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnosis and Monitoring of Polymyositis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Diagnostics and treatment of polymyalgia rheumatica].

Zeitschrift fur Rheumatologie, 2016

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.